Pictet Asset Management Holding SA Lowers Stake in IQVIA Holdings Inc. $IQV

by · The Cerbat Gem

Pictet Asset Management Holding SA lessened its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 4.7% in the 4th quarter, Holdings Channel reports. The firm owned 95,177 shares of the medical research company’s stock after selling 4,729 shares during the period. Pictet Asset Management Holding SA’s holdings in IQVIA were worth $21,454,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the fourth quarter worth $25,000. Physician Wealth Advisors Inc. raised its stake in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares in the last quarter. Westside Investment Management Inc. lifted its holdings in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new position in shares of IQVIA during the 3rd quarter worth about $30,000. Finally, Atlantic Union Bankshares Corp acquired a new position in shares of IQVIA during the 3rd quarter worth about $36,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Up 1.2%

Shares of IQVIA stock opened at $158.47 on Friday. The company has a market cap of $26.89 billion, a P/E ratio of 20.16, a PEG ratio of 1.56 and a beta of 1.39. The firm has a fifty day moving average of $169.36 and a two-hundred day moving average of $201.57. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.5 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on IQV shares. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Jefferies Financial Group dropped their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Evercore restated an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Finally, Morgan Stanley set a $240.00 target price on shares of IQVIA in a research report on Wednesday, February 11th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $226.63.

Check Out Our Latest Analysis on IQVIA

About IQVIA

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Read More

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).